Understanding Medicare and Weight Loss Drugs: What Beneficiaries Need to Know

Wondering if Medicare covers weight loss medications? Talk with a DevotedDOc healthcare provider.

For many years, Medicare generally did not cover prescription medications used solely for weight loss. That left many beneficiaries paying out of pocket for newer glucagon-like peptide-1 (GLP-1) medications, even when their healthcare providers recommended them as part of a comprehensive obesity treatment plan.

That changed on July 1, 2026, when Medicare introduced the Medicare GLP-1 Bridge Program. Through this temporary nationwide program, eligible beneficiaries with Medicare Part D can receive coverage for select GLP-1 medications used for chronic weight management, including Wegovy, Zepbound KwikPen, and Foundayo, for a $50 monthly copayment. However, coverage is not available to everyone, and beneficiaries must meet specific eligibility requirements established by the Centers for Medicare & Medicaid Services (CMS).

As Medicare expands coverage, many beneficiaries remain unsure which medications the program covers, who qualifies, and how the process works. Some also wonder whether Medicare applies different coverage rules to weight loss, diabetes, and other approved medical conditions.

This guide explains how Medicare and weight loss drugs work today, which medications are currently covered, and what beneficiaries should know before starting treatment. If you’d like a detailed overview of the current program, visit our guide to GLP-1 coverage.

How Medicare Covers Weight Loss Drugs Today

Today, Medicare prescription drug coverage for weight loss medications follows two different pathways.

The first is the temporary Medicare GLP-1 Bridge Program, which began on July 1, 2026. This nationwide demonstration allows eligible Medicare Part D beneficiaries to receive coverage for select GLP-1 medications prescribed for chronic weight management. The program operates separately from a beneficiary’s standard Part D prescription drug benefit and currently runs through December 31, 2027. During this period, eligible patients pay a flat $50 monthly copayment for covered medications.

The second pathway uses traditional Medicare Part D coverage. Medicare Part D may cover certain GLP-1 medications when healthcare providers prescribe them for FDA-approved indications other than obesity. These may include type 2 diabetes, cardiovascular risk reduction, or other qualifying medical conditions. In these situations, the beneficiary’s regular Medicare Part D plan handles coverage instead of the temporary Bridge Program.

Understanding which pathway applies is important because eligibility requirements, prior authorization, cost sharing, and claims processing depend on why the healthcare provider prescribes the medication.

Which Weight Loss Drugs Are Covered by Medicare?

One of the biggest questions beneficiaries ask is which medications Medicare covers for weight management. Although several GLP-1 medications are available today, Medicare’s temporary weight loss program does not include every medication or formulation.

Under the current Medicare GLP-1 Bridge Program, eligible beneficiaries may receive coverage for three FDA-approved medications used for chronic weight management:

• Wegovy®
• Zepbound® KwikPen®
• Foundayo®

It’s important to note that the program does not cover single-dose Zepbound vials or single-dose pens. Only the multi-dose Zepbound KwikPen qualifies under the current Medicare Bridge Program.

Wegovy®

Wegovy is one of the GLP-1 medications covered through the Medicare GLP-1 Bridge Program for eligible beneficiaries. It is FDA-approved for chronic weight management and is intended to be used alongside a reduced-calorie diet and increased physical activity. Depending on Medicare program requirements and your treatment plan, eligible beneficiaries may receive coverage for injectable or oral Wegovy through the Bridge Program.

If you’re considering this medication, your healthcare provider can determine whether you meet the program’s eligibility requirements and whether Wegovy is appropriate for your individual health needs.

If you’d like to learn more about the approval process, read our guide on how to get Wegovy covered by Medicare.

Zepbound® KwikPen®

Zepbound KwikPen is another medication available through the Medicare GLP-1 Bridge Program. However, Medicare specifically covers the KwikPen formulation. Single-dose Zepbound pens and vials are not included under the current program.

Like other GLP-1 medications, Zepbound KwikPen should be used as part of a comprehensive weight management plan that includes healthy eating and regular physical activity. Your healthcare provider will determine whether this medication is appropriate based on your medical history and treatment goals.

Foundayo®

Foundayo is the first oral GLP-1 medication included in the Medicare GLP-1 Bridge Program. Unlike weekly injectable therapies, Foundayo is taken once daily by mouth and may appeal to beneficiaries who prefer an oral treatment option.

According to the FDA prescribing information, Foundayo should be taken whole without crushing or chewing and is approved for chronic weight management when combined with a reduced-calorie diet and increased physical activity. Whether Foundayo is the right choice depends on factors such as your health history, lifestyle, and your healthcare provider’s recommendations.

Because Medicare now covers both oral and injectable GLP-1 medications, beneficiaries have more treatment options than ever before.

What Beneficiaries Should Know Before Starting GLP-1 Treatment

Starting a GLP-1 medication involves more than receiving a prescription. Medicare requires eligible beneficiaries to meet certain program requirements, and healthcare providers play an important role throughout the treatment process.

Understanding these requirements ahead of time can help you prepare for a smoother experience if you’re considering Medicare obesity treatment through the Medicare GLP-1 Bridge Program.

Your Healthcare Provider Must Confirm Eligibility

Before Medicare approves coverage through the Bridge Program, your healthcare provider must determine that you meet the program’s eligibility criteria.

If you qualify, your provider will:

• Evaluate your medical history and weight-related health conditions
• Prescribe a covered GLP-1 medication
• Complete a prior authorization if Medicare requests one
• Certify that you’re participating in a lifestyle program focused on healthy eating and physical activity

Once Medicare approves the request, you’ll receive a letter confirming your coverage under the Medicare GLP-1 Bridge Program. Prior authorization remains valid through December 31, 2027, including approved refills and dose adjustments, unless you switch to a different GLP-1 medication.

Lifestyle Changes Remain an Important Part of Treatment

GLP-1 medications are intended to support—not replace—healthy lifestyle habits.

Whether you take an injectable medication like Wegovy or Zepbound KwikPen or an oral option like Foundayo, you should combine treatment with a reduced-calorie diet and increased physical activity. Foundayo’s FDA-approved prescribing information also recommends using the medication as part of a chronic weight management plan that includes healthy eating and regular exercise.

Your healthcare provider will typically monitor your progress over time and may adjust your treatment plan based on your response, any side effects, and your overall health goals.

Follow Your Medication Exactly as Prescribed

Each GLP-1 medication has its own dosing schedule and administration instructions.

For example, Foundayo is taken once daily by mouth, while Zepbound KwikPen is administered once weekly using a multi-dose injection pen. Because these medications have different dosing schedules and instructions, it’s important to follow your healthcare provider’s guidance and the manufacturer’s prescribing information.

If you’re exploring your options, our weight loss treatment program can help determine whether a GLP-1 medication is appropriate for your individual health needs and treatment goals.

Common Misunderstandings About Medicare Weight Loss Drug Coverage

As Medicare expands access to GLP-1 medications, many beneficiaries have questions about what is—and is not—covered. Understanding a few common misconceptions can help you avoid surprises during the approval process.

“Medicare Covers Every GLP-1 Medication”

Not necessarily.

While Medicare now covers certain GLP-1 medications through the temporary Bridge Program, it limits coverage to specific medications that meet the program’s requirements. At this time, the program includes Foundayo, Wegovy, and Zepbound KwikPen for eligible beneficiaries. A beneficiary’s regular Medicare Part D plan may also cover other GLP-1 medications when a healthcare provider prescribes them for different FDA-approved indications, such as type 2 diabetes.

“If I Have Medicare Part D, I’ll Automatically Qualify”

Having Medicare Part D is only one part of the eligibility process.

Beneficiaries must also meet the Medicare GLP-1 Bridge Program’s clinical eligibility requirements. In addition, a healthcare provider must prescribe the medication, complete prior authorization when requested, and certify that treatment is part of a lifestyle program focused on diet and exercise.

“Every Version of the Medication Is Covered”

Coverage may vary depending on the specific formulation.

For example, the Medicare GLP-1 Bridge Program covers Zepbound KwikPen, but it does not cover single-dose Zepbound vials or single-dose pens. Beneficiaries should confirm that the prescribed product matches the version included in the program before filling their prescription.

“Coverage Means I Won’t Need Ongoing Follow-Up”

GLP-1 treatment is designed to support long-term weight management, not simply provide a prescription.

Your healthcare provider may schedule follow-up visits to monitor your progress, evaluate your response to treatment, manage any side effects, and adjust your treatment plan when necessary. You should also continue following your recommended nutrition and physical activity plan throughout treatment.

“Medicare Coverage for Weight Loss Drugs Is Permanent”

The current Medicare GLP-1 Bridge Program is temporary.

Under current CMS guidance, the program is scheduled to remain in effect through December 31, 2027. CMS has not yet announced whether it will extend the program or replace it with a permanent coverage pathway. Beneficiaries should watch for future Medicare updates as the program approaches its scheduled end date.

Frequently Asked Questions About Medicare and Weight Loss Drugs

Learn More About Weight Loss Treatment Options

Understanding Medicare and weight loss drugs can help you make informed decisions about your treatment options. Whether you’re exploring GLP-1 medications for the first time or want to better understand your Medicare coverage, speaking with a qualified healthcare provider is an important first step.

At DevotedDOc, we offer personalized weight loss treatment to help eligible patients determine whether GLP-1 therapy may be appropriate based on their medical history, health goals, and current coverage options.

Ready to take the next step? Schedule an appointment with a DevotedDOc healthcare provider to discuss your treatment options and see whether you may qualify for GLP-1 therapy.